Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2845-2854

  Kaliberova, Lyudmila N ^a   Della Manna, Debbie L ^a   Krendelchtchikova, Valentina ^a   Black, Margaret E ^b   Buchsbaum, Donald J ^a   Kaliberov, Sergey A ^a  

^a The University of Alabama at Birmingham   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL CYTOSINE DEAMINASE; BACTERIAL ENZYME; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; CANCER INHIBITION; CELL SURVIVAL; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO CULTURE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TUMOR VOLUME; XENOGRAFT;

ADENOVIRIDAE; AMINO ACID SUBSTITUTION; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL DEATH; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; CYTOSINE DEAMINASE; ESCHERICHIA COLI; FEMALE; FLUCYTOSINE; GENE THERAPY; HUMANS; MICE; MICE, NUDE; MUTANT PROTEINS; PANCREATIC NEOPLASMS; RADIATION, IONIZING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54049150469     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0347     Document Type: Article

References (43)

1. Berlin JD, Rothenberg ML. Chemotherapeutic advances in pancreatic cancer. Curr Oncol Rep 2003;5:219-26.
2. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007;34:347-53.
3. Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP 2007;8:545-52.
4. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005;16:349-59.
5. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res 1998;58:2588-93.
6. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003;13:13-21.
7. Evoy D, Hirschowitz EA, Naama HA, et al. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res 1997;69:226-31.
8. Pan X, Li ZS, Xu GM, Cui L, Tu ZX. Adenovirus-mediated gene transfer in the treatment of pancreatic cancer. Pancreas 2003;26:274-8.
9. Wang XP, Yazawa K, Yang J, Kohn D, Fisher WE, Brunicardi FC. Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. J Gastrointest Surg 2004;8:98-108; discussion 6-8.
10. Mahan SD, Ireton GC, Stoddard BL, Black ME. Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference. Biochemistry 2004;43:8957-64.
11. Mahan SD, Ireton GC, Knoeber C, Stoddard BL, Black ME. Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy. Protein Eng Des Sel 2004;17:625-33.
12. Pederson LC, Buchsbaum DJ, Vickers SM, et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangio-carcinoma cells in vitro and in vivo. Cancer Res 1997;57:4325-32.
13. Kaliberov SA, Markert JM, Gillespie GY, et al. Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma. Gene Ther 2007;14:1111-9.
14. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
15. Moertel CG, Childs DS, Jr., Reitemeier RJ, Colby MY, Jr., Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-7.
16. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-10.
17. Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA. Future chemoradiation strategies in pancreatic cancer. Semin Oncol 2007;34:335-46.
18. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994;1:170-5.
19. Haack K, Linnebacher M, Eisold S, Zoller M, von Knebel Doeberitz M, Gebert J. Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther 2000;7:1357-64.
20. Kaliberov SA, Chiz S, Kaliberova LN, et al. Combination of cytosine deaminse suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity. Cancer Gene Ther 2006;13:203-14.
21. Zhang SN, Yuan SZ, Zhu ZH, Wen ZF, Huang ZQ, Zeng ZY. Apoptosis induced by 5-flucytosine in human pancreatic cancer cells genetically modified to express cytosine deaminase. Acta Pharmacol Sin 2000;21:655-9.
22. Etienne MC, Cheradame S, Fischel JL, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-70.
23. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
24. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors respondingto 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-7.
25. Inaba M, Naoe Y, Mitsuhashi J. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells. Biol Pharm Bull 1998;21:569-73.
26. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-82.
27. Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res 1993;53:3677-80.
28. Miller EM, Kinsella TJ. Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 1992;52:1687-94.
29. Lawrence TS, Tepper JE, Blackstock AW. Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol 1997;7:260-6.
30. McGinn CJ, Lawrence TS. Recent advances in the use of radio-sensitizing nucleosides. Semin Radiat Oncol 2001;11:270-80.
31. Davis MA, Tang HY, Maybaum J, Lawrence TS. Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. Int J Radiat Biol 1995;67:509-17.
32. Lawrence TS, Davis MA, Loney TL. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res 1996;56:3203-6.
33. Motoi F, Sunamura M, Ding L, et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther 2000;11:223-35.
34. Oonuma M, Sunamura M, Motoi F, et al. Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosiltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors. Int J Cancer 2002;102:51-9.
35. Saito Y, Sunamura M, Motoi F, et al. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther 2006;13:242-52.
36. Cabrele C, Vogel M, Piso P, et al. 5-Fluorouracil-related enhancement of adenoviral infection is coxsackievirus-adenovirus receptor independent and associated with morphological changes in lipid membranes. World J Gastroenterol 2006;12:5168-74.
37. Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res 2002;21:6089-98.
38. Conrad C, Miller CR, Ji Y, et al. Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 2005;12:284-94.
39. Liu Y, Deisseroth A. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Ther 2006;13:845-55.
40. Liu Y, Ye T, Sun D, Maynard J, Deisseroth A. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes. Gene Ther 2006;13:1235-43.
41. Freytag SO, Movsas B, Aref I, et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 2007;15:1016-23.
42. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003;63:7497-506.
43. Freytag SO, Barton KN, Brown SL, et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007;15:1600-6.